

Pritelivir

Catalog No: tcsc1693



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

348086-71-5

Formula:

$C_{18}H_{18}N_4O_3S_2$

Pathway:

Anti-infection

Target:

HSV

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 33 mg/mL (81.99 mM)

Alternative Names:

BAY 57-1293;AIC316

Observed Molecular Weight:

402.49


Product Description

Pritelivir (BAY 57-1293; AIC316) represents a new class of potent inhibitors of herpes simplex virus (HSV) that target the virus helicase primase complex.

IC50 & Target: IC50: 20 nM (HSV-1) [1]

In Vitro: BAY 57-1293 is nearly two orders of magnitude more potent than acyclovir in vitro and the superiority was even more prominent when the viral load was increased (BAY 57-1293 IC50 = 12 nM, 20 nM and 50 nM; acyclovir IC50 = 1 μM, 3 μM and 10-50 μM at a multiplicity of infection (m.o.i.) of 0.0025, 0.02 and 0.2, respectively). A minor increase in IC50 values at higher viral loads was observed for all thiazolyl compounds listed in Table 1. BAY 57-1293 was also active against porcine (IC50 = 5 μM) and bovine (IC50 = 0.12 μM) herpes strains [1].

In Vivo: Delayed treatment with BAY 57-1293 (20 mg/kg 2× daily per os, treatment day 4-14) abrogates progression of disease symptoms (mean of 10 animals per group) of HSV-2 infected guinea pigs within 1 d of treatment and healing is observed subsequently, whereas a 7.5 fold higher dose of valacyclovir (150 mg/kg 2× daily) shows marginal therapeutic efficacy compared with placebo [1]. The compound given orally, or intraperitoneally once per day at a dose of 15 mg/kg for 4 successive days was equally effective or superior to a much higher dose of famciclovir (1 mg/ml, i.e. approximately 140-200 mg/kg/day) given in the drinking water for 7 consecutive days, which, in our hands, is the most effective method for administering famciclovir to mice [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!